More news
- Nigeria’s paint industry navigates regulatory changes and economic challenges amid p...
- Focus on the global coatings market: Global coatings market outlook
- Ask Joe Powder – October 2024
- Chinese paint majors look to domestic consumer sales as commercial real estate slumps
- Architectural coatings in Nepal and Bhutan
The Vitex with VAIRO paint has received the approval for circulation in EU markets* and mass production has started. To mark the launch, Vitex S.A. has donated significant quantity to two leading public hospitals: Onassis Cardiac Surgery Center and the Agios Savvas Anti-Caner Hospital, each one being the leading institution at its field. The launch has also been endorsed by the Athens Medical Group, the largest private health provider in Greece.
Vitex with VAIRO is an innovative paint for interior walls with proven antiviral and antibacterial properties on painted surfaces. By applying Vitex with VAIRO paint, viruses and bacteria – including SARS-CoV2 – are eliminated and their ability to be transmitted through painted surfaces is virtually nullified in 30 minutes to four hours of contact. This "extra barrier” for SARS-CoV2 transmission is especially important for the protection of high traffic areas e.g. hospitals, schools, aged care facilities, hotels and shopping malls.
Vitex with VAIRO was developed by using the integration of suitable antimicrobial structures into the paint, which based on silver ions and the utilisation of interfacial tension phenomena, where a slippery hydrophilic coating surface unfolds, which proved to be inhospitable for viruses and bacteria including SARS-CoV2, influenza virus H1N1, bacteriophage phi6, as surrogate for Coronavirus, Ebola, ΗΙV, Influenza Viruses, Escherichia Coli, Human Coronavirus SARS-CoV2, Human Coronavirus OC43, Human Coronavirus 229E, Influenza virus H1N1, Bacteriophage phi6, as surrogate for Coronavirus, Ebola, ΗΙV, Influenza Viruses, Bacteriophage MS2 as surrogate for Norovirus and others, Escherichia Coli, Staphylococcus Aureus, Pseudomonas Aeruginosa, Enterococcus Hirae and Klebsiella Pneumoniae.
*Great Britain (HSE) – Meets regulatory requirements to be placed in the market
*Germany (Baua) – Registration number N-98709
*France (ANSES) – Registration number 67513
*Malta (MCCAA) – Notification reference no.: 2021-03-26-B08
*Croatia (Ministry of Health Republic of Croatia) – Authorisation Number 534-03-3-2/8-21-2
*Bulgaria (Ministry of Health Republic of Bulgaria) – Authorisation Number 3171-1 / 22.06.2021
*Cyprus (Ministry of Agriculture, Rural Development and Environment) – Authorisation Number Β2210
*Greece (NOM) Authorisation Number 90167/04-10-2021